ABBV - AbbVie Inc Stock Price, Fair Value and News

160.71USD-1.84 (-1.13%)Delayed as of 08 May 2024, 03:40 pm ET

Market Summary

USD160.71-1.84

Delayedas of 08 May 2024, 03:40 pm

-1.13%

ABBV Alerts

Big jump in Earnings (Y/Y)

ABBV Stock Price

View Fullscreen

ABBV RSI Chart

ABBV Valuation

Market Cap

286.8B

Price/Earnings (Trailing)

47.94

Price/Sales (Trailing)

5.27

EV/EBITDA

30.94

Price/Free Cashflow

13.1

ABBV Price/Sales (Trailing)

ABBV Profitability

EBT Margin

13.84%

Return on Equity

74.35%

Return on Assets

4.02%

Free Cashflow Yield

7.63%

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

54.4B

Rev. Growth (Yr)

0.7%

Rev. Growth (Qtr)

-13.92%

ABBV Earnings

Earnings (TTM)

6.0B

Earnings Growth (Yr)

468.62%

Earnings Growth (Qtr)

65.33%

Breaking Down ABBV Revenue

52 Week Range

130.96162.70

(Low)(High)

Last 7 days

-0.1%

Last 30 days

-4.4%

Last 90 days

-7.2%

Trailing 12 Months

10.2%

How does ABBV drawdown profile look like?

ABBV Financial Health

Current Ratio

0.94

Debt/Equity

7.93

Debt/Cashflow

0.36

ABBV Investor Care

Dividend Yield

1.61%

Dividend/Share (TTM)

2.63

Shares Dilution (1Y)

0.09%

Diluted EPS (TTM)

3.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	54.4B	0	0	0
2023	56.7B	56.0B	55.1B	54.3B
2022	56.7B	57.3B	57.8B	58.1B
2021	50.2B	53.7B	55.2B	56.2B
2020	34.1B	36.2B	40.6B	45.8B
2019	32.6B	32.6B	32.9B	33.3B
2018	29.6B	30.9B	32.2B	32.8B
2017	26.2B	26.7B	27.3B	28.2B
2016	23.8B	24.8B	25.2B	25.6B
2015	20.4B	21.0B	21.9B	22.9B
2014	19.0B	19.3B	19.6B	20.0B
2013	18.5B	18.7B	18.9B	18.8B
2012	17.7B	17.9B	18.1B	18.4B
2011	0	0	0	17.4B
2010	0	0	0	15.6B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AbbVie Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	davis jennifer l.	acquired	-	-	1,322	-
May 03, 2024	waddell frederick h	acquired	-	-	1,322	-
May 03, 2024	freyman thomas c	acquired	-	-	1,322	-
May 03, 2024	tilton glenn f	acquired	-	-	1,322	-
May 03, 2024	rapp edward j	acquired	-	-	1,322	-
May 03, 2024	meyer melody b	acquired	-	-	1,322	-
May 03, 2024	austin roxanne s	acquired	-	-	1,322	-
May 03, 2024	quaggin susan e	acquired	-	-	1,322	-
May 03, 2024	alpern robert j	acquired	-	-	1,322	-
May 03, 2024	roberts rebecca b	acquired	-	-	1,322	-

Which funds bought or sold ABBV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	reduced	-3.7	5,132,140	44,125,400	0.44%
May 06, 2024	Broderick Brian C	added	15.29	601,429	2,296,650	0.49%
May 06, 2024	Oxbow Advisors, LLC	added	4.16	245,301	1,340,100	0.18%
May 06, 2024	First Long Island Investors, LLC	reduced	-2.1	3,411,660	26,099,100	2.17%
May 06, 2024	Summit Asset Management, LLC	added	0.04	133,331	893,840	0.19%
May 06, 2024	First Business Financial Services, Inc.	unchanged	-	-	1,140,420	0.13%
May 06, 2024	Manchester Capital Management LLC	added	12.89	988,529	4,016,180	0.49%
May 06, 2024	Cohen Capital Management, Inc.	unchanged	-	272,060	1,826,100	0.32%
May 06, 2024	TEXAS PERMANENT SCHOOL FUND CORP	added	0.12	9,964,530	66,443,200	0.52%
May 06, 2024	STALEY CAPITAL ADVISERS INC	unchanged	-	51,411	345,079	0.02%

Are Funds Buying or Selling ABBV?

Are funds buying ABBV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABBV

No. of Funds

ABBV Alerts

Big jump in Earnings (Y/Y)

Unveiling AbbVie Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.08%	160,380,057	SC 13G/A
Jan 25, 2024	blackrock inc.	8.1%	143,180,060	SC 13G/A
Feb 16, 2023	blackrock inc.	7.8%	138,702,758	SC 13G/A
Feb 09, 2023	vanguard group inc	8.95%	158,317,552	SC 13G/A
Feb 09, 2022	vanguard group inc	8.28%	146,312,069	SC 13G/A
Feb 03, 2022	blackrock inc.	7.3%	128,197,555	SC 13G/A
Feb 16, 2021	capital research global investors	2.1%	37,921,062	SC 13G/A
Feb 10, 2021	vanguard group inc	8.08%	142,563,074	SC 13G/A
Jan 29, 2021	blackrock inc.	7.0%	124,423,484	SC 13G/A
Feb 14, 2020	capital research global investors	5.8%	86,602,693	SC 13G/A

Recent SEC filings of AbbVie Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading

Peers (Alternatives to AbbVie Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

AbbVie Inc News

Latest updates

AbbVie Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-13.9%	12,310	14,301	13,927	13,865	12,225	15,121	14,812	14,583	13,538	14,886	14,342	13,959	13,010	13,858	12,902	10,425	8,619	8,704	8,479	8,255	7,828
Costs and Expenses	-14.4%	9,512	11,106	11,646	9,352	9,457	9,619	10,209	11,288	8,821	9,812	10,036	9,518	8,907	10,105	9,647	9,673	5,016	4,748	5,862	4,855	4,818
S&GA Expenses	3.8%	3,315	3,193	3,372	3,268	3,039	3,417	3,304	5,412	3,127	3,260	3,083	3,164	2,842	3,231	2,846	3,527	1,695	1,951	1,657	1,654	1,680
EBITDA Margin	13.3%	0.20*	0.17*	0.21*	0.25*	0.22*	0.29*	0.32*	0.31*	0.31*	0.29*	0.19*	0.18*	-	-	-	-	-	-	-	-	-
Income Taxes	-1.3%	383	388	172	583	234	493	448	255	436	226	508	394	312	-1,545	187	46.00	88.00	273	117	66.00	88.00
Earnings Before Taxes	44.8%	1,755	1,212	1,953	2,610	475	2,965	4,400	1,183	4,929	4,271	3,688	1,163	3,867	-1,507	2,500	-693	3,098	3,074	2,001	807	2,544
EBT Margin	20.3%	0.14*	0.12*	0.15*	0.19*	0.16*	0.23*	0.26*	0.25*	0.25*	0.23*	0.13*	0.11*	-	-	-	-	-	-	-	-	-
Net Income	65.3%	1,359	822	1,778	2,024	239	2,473	3,949	924	4,490	4,044	3,179	766	3,553	36.00	2,308	-738	3,010	2,801	1,884	741	2,456
Net Income Margin	22.8%	0.11*	0.09*	0.12*	0.16*	0.13*	0.20*	0.23*	0.22*	0.22*	0.21*	0.14*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	-15.4%	3,847	4,548	7,355	6,141	4,018	7,215	7,425	4,862	4,746	4,888	7,718	4,695	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	10.5%	148,874	134,711	136,221	135,367	134,544	138,805	141,325	143,186	143,211	146,529	148,858	147,972	150,501	150,565	149,621	149,530	91,199	89,115	59,441	57,142	56,769
Current Assets	17.8%	38,871	33,002	33,224	28,852	26,488	28,463	30,364	29,100	26,509	27,928	28,957	25,999	26,569	24,173	23,009	21,256	51,758	49,519	20,166	15,100	14,413
Cash Equivalents	41.0%	18,067	12,814	13,287	8,759	6,711	9,201	11,832	8,521	6,098	9,746	12,182	8,546	9,755	8,449	7,890	6,017	41,142	39,924	10,648	5,172	4,897
Inventory	3.6%	4,245	4,099	3,981	4,055	3,833	3,579	3,172	3,396	3,483	3,128	3,094	3,386	3,272	3,310	3,474	4,059	1,844	1,813	1,929	1,895	1,702
Net PPE	-0.2%	4,980	4,989	4,934	4,943	4,931	4,935	4,893	4,958	5,075	5,110	5,130	5,161	5,193	5,248	4,986	4,908	2,961	2,962	2,894	2,879	2,860
Goodwill	3.5%	33,426	32,293	32,091	32,224	32,220	32,156	31,726	32,028	32,298	32,379	32,296	32,398	32,349	33,124	42,801	42,669	15,561	15,604	15,537	15,642	15,606
Current Liabilities	9.7%	41,522	37,841	34,773	32,239	27,590	29,538	32,712	34,473	32,521	35,194	28,533	28,684	31,951	28,661	24,181	24,646	16,471	15,585	17,493	16,941	13,904
Short Term Borrowings	-	3.00	-	2.00	-	1.00	1.00	10.00	17.00	12.00	14.00	16.00	17.00	9.00	34.00	54.00	64.00	6.00	-	-	306	499
Long Term Debt	22.2%	63,805	52,194	55,631	55,812	59,292	59,135	60,399	61,002	63,522	64,189	74,049	74,237	74,183	77,554	82,282	82,061	63,284	62,975	33,126	31,619	35,066
Shareholder's Equity	-22.3%	8,047	10,360	12,094	12,898	13,303	17,254	16,027	14,688	16,314	15,436	13,577	12,594	13,733	13,097	15,289	14,732	-	-	-	-	-
Retained Earnings	-138.4%	-2,384	-1,000	933	1,789	2,393	4,784	4,953	3,516	5,103	3,127	1,600	740	2,292	1,055	3,335	3,130	5,973	4,717	3,673	3,384	4,234
Additional Paid-In Capital	2.4%	20,656	20,180	20,021	19,839	19,619	19,245	19,056	18,906	18,731	18,305	18,108	17,936	17,712	17,384	17,148	16,953	15,401	15,193	15,112	15,028	14,940
Shares Outstanding	0.1%	1,769	1,768	1,768	1,768	1,770	1,771	1,771	1,770	1,771	1,770	1,769	1,769	-	-	-	-	-	-	-	-	-
Minority Interest	8.1%	40.00	37.00	35.00	32.00	29.00	33.00	33.00	35.00	31.00	28.00	27.00	25.00	23.00	21.00	19.00	24.00	-	-	-	-	-
Float	-	-	-	-	235,630	-	-	-	268,253	-	-	-	197,246	-	-	-	171,597	-	-	-	106,362	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.0%	4,040	4,753	7,574	6,319	4,193	7,428	7,602	5,005	4,908	5,075	7,935	4,890	4,877	4,854	5,830	3,089	3,815	3,275	4,555	2,477	3,017
Share Based Compensation	178.4%	348	125	130	179	313	132	126	107	306	129	135	159	269	136	162	236	219	79.00	75.00	87.00	189
Cashflow From Investing	-1098.5%	-9,588	-800	-369	-341	-499	-448	1,286	130	-1,591	-1,145	-615	-242	-342	-627	-1,149	-35,652	-129	-615	1,378	-140	-27.00
Cashflow From Financing	343.2%	10,819	-4,449	-2,661	-3,920	-6,192	-9,634	-5,518	-2,679	-6,972	-6,338	-3,643	-5,884	-3,174	-3,695	-2,814	-2,570	-2,422	26,602	-441	-2,070	-5,383
Dividend Payments	5.6%	2,772	2,626	2,627	2,625	2,661	2,506	2,504	2,507	2,526	2,314	2,315	2,310	2,322	2,101	2,100	1,752	1,763	1,595	1,591	1,592	1,588
Buy Backs	44033.3%	1,324	3.00	4.00	10.00	1,955	4.00	4.00	9.00	1,470	131	6.00	10.00	787	296	20.00	19.00	643	2.00	4.00	3.00	620

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABBV Income Statement

2024-03-31

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenues	$ 12,310	$ 12,225
Cost of products sold	4,094	3,986
Selling, general and administrative	3,315	3,039
Research and development	1,939	2,292
Acquired IPR&D and milestones	164	150
Other operating income	0	(10)
Total operating costs and expenses	9,512	9,457
Operating earnings	2,798	2,768
Interest expense, net	453	454
Net foreign exchange loss	4	35
Other expense, net	586	1,804
Earnings before income tax expense	1,755	475
Income tax expense	383	234
Net earnings	1,372	241
Net earnings attributable to noncontrolling interest	3	2
Net earnings attributable to AbbVie Inc.	$ 1,369	$ 239
Per share data
Basic earnings per share (in dollars per share)	$ 0.77	$ 0.13
Diluted earnings per share (in dollars per share)	$ 0.77	$ 0.13
Weighted-average basic shares outstanding (in shares)	1,769	1,770
Weighted-average diluted shares outstanding (in shares)	1,773	1,776

ABBV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and equivalents	$ 18,067	$ 12,814
Short-term investments	2	2
Accounts receivable, net	11,949	11,155
Inventories	4,245	4,099
Prepaid expenses and other	4,608	4,932
Total current assets	38,871	33,002
Investments	305	304
Property and equipment, net	4,980	4,989
Intangible assets, net	62,225	55,610
Goodwill	33,426	32,293
Other assets	9,067	8,513
Total assets	148,874	134,711
Current liabilities
Short-term borrowings	3	0
Current portion of long-term debt and finance lease obligations	10,193	7,191
Accounts payable and accrued liabilities	31,326	30,650
Total current liabilities	41,522	37,841
Long-term debt and finance lease obligations	63,805	52,194
Deferred income taxes	2,722	1,952
Other long-term liabilities	32,778	32,327
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,829,957,662 shares issued as of March 31, 2024 and 1,823,046,087 as of December 31, 2023	18	18
Common stock held in treasury, at cost, 64,234,512 shares as of March 31, 2024 and 57,105,354 as of December 31, 2023	(7,829)	(6,533)
Additional paid-in capital	20,656	20,180
Accumulated deficit	(2,384)	(1,000)
Accumulated other comprehensive loss	(2,454)	(2,305)
Total stockholders' equity	8,007	10,360
Noncontrolling interest	40	37
Total equity	8,047	10,397
Total liabilities and equity	$ 148,874	$ 134,711

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal BehÃƒÂ§et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

CEO	Mr. Richard A. Gonzalez
WEBSITE	abbvie.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	50000

AbbVie Inc Frequently Asked Questions

What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbbVie Inc (ABBV)?

As of Tue May 07 2024, market cap of AbbVie Inc is 286.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers. The fair value of AbbVie Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbbVie Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABBV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbbVie Inc a good stock to buy?

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, ABBV's PE ratio (Price to Earnings) is 47.94 and Price to Sales (PS) ratio is 5.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AbbVie Inc's stock?

In the past 10 years, AbbVie Inc has provided 0.16 (multiply by 100 for percentage) rate of return.